
Melanotan I
Also called afamelanotide (see approved)
- Evidence
- Limited research
- Class
- MC1R agonist
Melanotan I belongs to the MC1R agonist class. This library groups it under skin & aging. Its source category is Not FDA-approved.
At a glance
| Compound class | MC1R agonist |
|---|---|
| Body system | Skin & aging |
| Use or research focus | Tanning/photoprotection |
| Regulatory status | Approved form = Scenesse; MT-I itself not approved |
| Source evidence rating | Limited research |
How does Melanotan I work?
Stimulates eumelanin.
The source catalog maps this mechanism to Skin. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
For an unapproved use or compound, safety and effectiveness may be uncertain. Products sold for research are not a substitute for prescribed care. Do not infer a human dose, injection protocol, or treatment recommendation from preclinical research.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is Melanotan I?
Melanotan I belongs to the MC1R agonist class. This library groups it under skin & aging. Its source category is Not FDA-approved. Its recorded use or research focus is: Tanning/photoprotection.
Is Melanotan I FDA-approved?
The catalog records: Approved form = Scenesse; MT-I itself not approved. Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Where can I read the research?
The Citations tab contains 3 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for skin & aging
Factual catalog fields and citation links are adapted from Superpower’s Melanotan I guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with Melanotan I in the source dataset. Open a source to review its study design, population, limitations, and date.
- 01rose an average of 41% in low-MED, burn-prone skinpubmed.ncbi.nlm.nih.gov
- 02168 adults with EPPpubmed.ncbi.nlm.nih.gov
- 03DOI: 10.1016/j.jpba.2012.11.040doi.org





